SCHEMBL7664787

SCHEMBL7664787

CC(C)(C)[Si](C)(C)OC[C@@H]1[C@@H](C/C=C\CCCC(=O)CO)[C@@H](OC2CCCCO2)C[C@H]1OC1CCCCO1

nearest known ligand 0.34

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.30
ADORA3 P0DMS8 1/20 0.30
ADRA2C P18825 1/20 0.30
SLC6A2 P23975 1/20 0.30
HTR2B P41595 1/20 0.30
MC3R P41968 1/20 0.30
SLC6A3 Q01959 1/20 0.30
PDE4D Q08499 1/20 0.30
SCN5A Q14524 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7664796 1.00 PGR (0.30) PGRADORA3ADRA2CSLC6A2HTR2B
SCHEMBL7664789 1.00 PGR (0.30) PGRADORA3ADRA2CSLC6A2HTR2B
SCHEMBL7671627 0.92
SCHEMBL7671619 0.92
SCHEMBL7671624 0.92
SCHEMBL7668019 0.92
SCHEMBL7668024 0.92
SCHEMBL7665603 0.92 TBXA2R (0.37)
SCHEMBL7665591 0.92 TBXA2R (0.37)
SCHEMBL7869363 0.92 TBXA2R (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6359181-B1 THERAPY FOR VISION DEFECTS ALLERGAN SALES, INC. 2002-03-19 US disclosed
US-6307092-B1 POTENT OCULAR HYPOTENSIVES AND ARE PARTICULARLY SUITED FOR THE MANAGEMENT OF GLAUCOMA. ALLERGAN SALES, INC. 2001-10-23 US disclosed
US-6248783-B1 GLAUCOMA THERAPY ALLERGAN SALES, INC. 2001-06-19 US disclosed